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Abstract
Genetic polymorphisms of the organic cation transporter 2 (OCT2), encoded by SLC22A2, have been investigated in
association with metformin disposition. A functional decrease in transport function has been shown to be associated with
the OCT2 variants. Using metabolomics, our study aims at a comprehensive monitoring of primary metabolite changes in
order to understand biochemical alteration associated with OCT2 polymorphisms and discovery of potential endogenous
metabolites related to the genetic variation of OCT2. Using GC-TOF MS based metabolite profiling, clear clustering of
samples was observed in Partial Least Square Discriminant Analysis, showing that metabolic profiles were linked to the
genetic variants of OCT2. Tryptophan and uridine presented the most significant alteration in SLC22A2-808TT homozygous
and the SLC22A2-808G.T heterozygous variants relative to the reference. Particularly tryptophan showed gene-dose effects
of transporter activity according to OCT2 genotypes and the greatest linear association with the pharmacokinetic
parameters (Clrenal,C l sec, Cl/F/kg, and Vd/F/kg) of metformin. An inhibition assay demonstrated the inhibitory effect of
tryptophan on the uptake of 1-methyl-4-phenyl pyrinidium in a concentration dependent manner and subsequent uptake
experiment revealed differential tryptophan-uptake rate in the oocytes expressing OCT2 reference and variant (808G.T).
Our results collectively indicate tryptophan can serve as one of the endogenous substrate for the OCT2 as well as
a biomarker candidate indicating the variability of the transport activity of OCT2.
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Introduction
The rapidly growing field of metabolomics has been regarded
as the most efficient and direct approach for validating
biochemical functions of putative enzymes and transporters,
identifying ligands for unknown enzyme functions, and identify-
ing and quantifying endogenous and exogenous chemicals in
tissues and body fluids [1–5]. This technology has been applied
to explore the protein activity and substrate selectivity of serine
hydrolase activities in complex proteomes [6] and to identify
important lipid substrates of fatty acid amide hydrolase using
solution-based in vitro enzyme assays [7]. The technology has
been further extended to genome-wide association studies of
metabolic phenotypes related to quantitative variations of single-
nucleotide polymorphisms and endogenous organic compounds
in human serum [8].
Organic cation transporter 2 (OCT2), encoded by SLC22A2,i s
important in the elimination of organic cations. The organic
cation substrates of OCT2 include model organic cations such as
tetraethylammonium (TEA) and decynium 22; clinically impor-
tant therapeutic drugs such as metformin [9], procainamide,
cisplatin, citalopram, and cimetidine; endogenous compounds
such as dopamine and norepinephrine; and toxic metabolites
such as pyridinium metabolites of haloperidol and 1-methyl-4-
phenyl pyridinium (MPP
+) [10–12]. As OCT2 is expressed
primarily in the basolateral membrane of kidney proximal
tubules, it is expected to play a leading role in renal elimination
of exogenous and endogenous substrates [10–12]. [13–15].
The SLC22A2-808G.T variant has been identified with an
allele frequency higher than 10% in all ethnic groups [12–14]. It
has been investigated as a contributing factor to the inter-
individual variation in the disposition and distribution of substrate
drugs [13–15]. The intrinsic clearances of MPP
+ and metformin,
substrates for OCT2, were decreased in oocytes, MDCK and
HEK-293 cells overexpressing the SLC22A2-808G.T variant
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genetic variation decreased the transport activity of OCT2 [13–
16]. As expected from the primary distribution of OCT2 in the
kidney, the 808G.T variant affected mainly tubular excretion and
renal clearance, increasing the plasma metformin level in subjects
expressing the 808G.T variant. The peak plasma concentration
(Cmax) of metformin was increased 1.62-fold in the SLC22A2-
808TT homozygous variant, and the area under the plasma
concentration versus time curve (AUClast) was increased 1.46- and
1.74-fold in SLC22A2-808GT heterozygous and 808TT homozy-
gous groups, respectively. The active secretion clearance (Clsec)o f
metformin is believed to represent an OCT2-mediated process
and is obtained by subtracting the creatinine clearance (Clcr) from
the renal clearance (Clrenal) of metformin. The Clsec of metformin
was decreased by 37.7% and 61.8% in the SLC22A2-808GT and
808TT variants, respectively, compared with the reference
genotype group [17].
To monitor the biochemical traits of the genetic OCT2 variants
and identify potential endogenous substrates, we performed a non-
targeted assignment of substrates to the transporter using gas
chromatography-mass spectrometry (GC-MS)-based metabolite
profiling. First, by comparing the levels of endogenous urine
metabolites among individuals with different OCT2 genotypes, we
showed that individuals expressing different OCT2 variants had
significantly dissimilar metabolic capacities. Then, all of the
identified metabolites and unknown compounds exhibiting
significant differences among the OCT2 variants were subjected
to regularized canonical correlation analysis (rCCA) to identify
correlations with various pharmacokinetic (PK) parameters of
metformin. Finally, in vitro functional studies of inhibitory effects
and uptake rates demonstrated that tryptophan can be an
endogenous substrate of OCT2.
Results
1. Metabolite profiles associated with different OCT2
variants indicate putative biomarkers for the variability of
OCT2 transport activity
OCT2 variants induce differential metabolome
composition and phenotype. We performed metabolite
profiling of urine samples obtained from carriers of three
different SLC22A2 genotypes. The genotypes of the 21 subjects
were SLC22A2 reference (7 males, 2 females), 808GT heterozygous
(4 males, 2 females), and 808TT homozygous (4 males, 2 females)
(Spreadsheet S1). A total of 85 metabolic signals were structurally
identified by GC-MS using the BinBase algorithm, with 80%
occurrence in at least one class of samples, which automatically
excluded known artifacts such as phthalates or polysiloxanes. The
endogenous metabolites included amino acids, carbohydrates,
amines, fatty acids, and organic acids. Particularly, it includes
xanthine, xanthosine, and uridine that are at very low cellular
levels in urine, whose detection was advantaged by high sensitivity
and scan rate of time-of-flight mass spectrometry technology along
with advanced deconvolution algorithm but it is not likely to be the
case for other analytical platform.
Multivariate analysis showed that the principal factors differen-
tiating the metabolic profiles were associated with the genetic
variants of SLC22A2. Only supervised partial least squares (PLS)
analysis could separate the three different genotypes with
application of the first three components (Figure 1A). Unsuper-
vised principal components analysis (PCA) only obscurely
differentiated the metabolite phenotypes between the reference
group and both variants (Figure S1). Univariate analysis of the
variance was used to interrogate compositional changes in
metabolites associated with SLC22A2 variants. Six metabolites
were significantly changed (p,0.01, Student’s t-test, Spreadsheet
S1) in homozygotes compared with the reference group. Among
those, tryptophan showed the most significant alteration
(p=0.00086). Other altered metabolites were oxoproline, 3-
hydroxy-3-methylglutaric acid, glucose, 2-hydroxyvaleric acid,
and uridine. In a comparison between heterozygotes and the
reference group, uridine was altered most drastically (p=0.0005);
13 other endogenous metabolites (p,0.01; Student’s t-test;
Spreadsheet S1) and tryptophan (p=0.0028) also showed
differences. Multi-comparison analysis (Scheffe ´’s test) supported
a significant alteration in both tryptophan and uridine, with the
highest levels of downregulation associated with each OCT2
variant compared with the reference group (Figure 1B, C). These
metabolites were endogenous substrate candidates potentially
related to the transport activity of OCT2.
Canonical correlation analysis reveals a strong
association between endogenous metabolites and PK
parameters of metformin. In the next approach, we applied
canonical correlation statistics to analyze the interactions between
metabolite compositions and PK parameters of metformin, which
was previously published by our laboratory [17]. Canonical
correlation analysis (CCA) is a multivariate analysis often applied
in psychological, climate, and ecological studies to quantify the
correlations between two separate data sets measured on the same
experimental units [18,19]. In the analysis, 85 identified
metabolites were introduced to regularized CCA with the
following eight metformin PK parameters: Cmax, AUClast,
elimination rate constant (Ke), body weight-normalized clearance
(Cl/F/kg), body weight-normalized volume of distribution (Vd/F/
kg), renal clearance (Clrenal), creatinine clearance (Clcre), and
secretion clearance (Clsec). The complete list of the metabolites and
metformin PK parameters is provided in Spreadsheet S1.
Figure 2 shows the CCA variables plot applied to the combined
data set, including all three SLC22A2 genotypes. The graphical
result of the canonical correlation with the first two canonical
dimensions (see Materials and Methods section) shows spatial
closeness between metabolites and metformin PK parameters.
Some variables were distinguished where the components
(metabolites and metformin PK parameters) were projected in
the same direction from the origin. The variables were nine
metabolites and four metformin PK parameters, including Clrenal,
Clsec, Cl/F/kg, and Vd/F/kg (canonical correlation, .0.70).
Among the clustered metabolites, tryptophan showed the greatest
distance from the origin, with close spatial relatedness to the
metformin PK parameters (Clrenal,C l sec, Cl/F/kg, and Vd/F/kg);
among the metformin PK parameters, Vd/F/kg showed the
greatest distance from the origin, implying the strongest correla-
tion with the metabolites. Three metabolites of the clustered
group, tryptophan, citrulline, and urea, were amine group-
containing compounds. The others were free fatty acids (palmitate
and stearate), 3-hydroxy-3-methylglutaric acid (HMG), and 3-
hydroxypropionic acid. No solid associations were observed for the
PK parameters and remaining metabolites including uridine,
which presented the greatest alteration in OCT2 variant, nor
pseudouridine, which shares structural similarity with uridine but
exists at the highest abundance among urine metabolites. Instead,
AUClast and Cmax were located in the opposite direction from the
main cluster, indicating a moderate level of negative correlation
with some of the metabolites.
To analyze the pairwise associations between metabolites and
metformin PK parameters in more detail, we constructed
a network based on the correlation results. In the network, the
variables X–Y (metabolites-PK parameters) represent relevant
Functional Metabolomic Study of OCT2 Substrate
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and Y in a pair-wise manner. As observed in Figure 3, Vd/F/kg
formed the highest degree of connectivity with all 29 endogenous
metabolites (canonical correlation, .0.60), and the strongest
association was with tryptophan (canonical correlation, 0.804).
Among the metabolites, tryptophan had the highest degree of
positive correlation with Clrenal,C l sec, and Cl/F/kg.
Additionally, we considered unknown compounds for linear
associations with the PK parameters of metformin. Forty-three
unknown compounds with the most significant differences among
the SLC22A2 genotypes (p,0.001, Spreadsheet S1) were added to
the metabolite list for the CCA analysis. As a result, four
compounds were significantly correlated with the PK parameters
(canonical correlation, .0.70). Their ID numbers were 234622,
267701, 267652, and 224529 (http://eros.fiehnlab.ucdavis.
edu:8080/binbase-compound/database/select Database). Never-
theless, among all metabolite variables considered, tryptophan
still presented the greatest association with Vd/F/kg and the
highest connectivity with the other PK parameters (Figure S2).
2. In vitro functional studies suggest that tryptophan can
serve as an endogenous substrate for OCT2
Tryptophan inhibition of OCT2-mediated MPP
+
uptake. Based on the metabolite profiling outcome, we used
some of the metabolites (glycine, taurine, uridine, and tryptophan)
in further in vitro functional studies. Uridine and tryptophan were
selected because their levels were the most significantly
downregulated in each OCT2 variant group compared with the
reference group. In particular, the downregulation of tryptophan
was intensified according to the genotype. Tryptophan was also
highly correlated with four metformin PK parameters (Clrenal,
Clsec, Cl/F/kg, and Vd/F/kg). Glycine and taurine, which were
significantly altered, but showed low and moderate levels of
correlation with metformin PK parameters respectively, were used
as negative controls for OCT2 uptake.
The ability of OCT2 to bind the different metabolites was
quantified by measuring the inhibitory effect of glycine (1–
100 mM), taurine (1–100 mM), uridine (1–100 mM), and trypto-
phan (0.01–10 mM) on OCT2-mediated uptake of MPP
+ in
oocytes expressing OCT2. TEA (0.01–1 mM), a known OCT2
inhibitor, was included as a positive control. Figure 4 compares the
inhibition of OCT2-mediated uptake by the metabolites at
multiple concentrations. Glycine and taurine at concentrations
of up to 100 mM showed no inhibition of MPP
+ uptake.
Tryptophan showed the strongest inhibition of MPP
+ uptake,
with an IC50 of 6.11 mM. Uridine had a weaker inhibitory effect,
with an IC50 of 51.5 mM, which is 8.43-fold that of tryptophan.
This result motivated further examination of tryptophan.
Differential tryptophan uptake in oocytes overexpressing
the OCT2 reference and 808G.T variant. The inhibition of
OCT2 substrate uptake by tryptophan suggested a strong affinity
of OCT2 for tryptophan. Therefore, we investigated the
differential rate of tryptophan uptake by the OCT2 reference
and 808G.T variant overexpressed in oocytes. Eight independent
replicates were analyzed, and each experiment included uptake
measurements of MPP
+ as a representative OCT2 substrate. The
uptakes of tryptophan and MPP
+ mediated by the OCT2
reference and variant were calculated by subtracting the uptake
rate in water-injected oocytes from that in OCT2-expressing
oocytes.
The uptake of both MPP
+ and tryptophan increased linearly for
1 h, and uptake measurements at 30 min were used for the
analysis. As expected, MPP
+ uptake was lower for the 808G.T
variant than for the reference protein (Figure 5). Within 30 min,
the rate was dramatically reduced from 2.9 to nearly 0 fmol/min/
oocyte overexpressing the 808G.T variant, consistent with what
we found in a previous study [15]. Tryptophan uptake also
displayed a lower translocation rate for the 808G.T variant, with
a significant reduction from 0.3 to 0.14 fmol/min/oocyte (2.0-
fold; p,0.05).
3. Substrate specificity of OCT2 for tryptophan compared
with that of other transporters
The substrate specificity of OCT2 for tryptophan was compared
with that of other transporters by testing tryptophan as an
inhibitor of four other transporters, OCT1, organic anion
transporter 1 (OAT1), organic anion transporting polypeptide
1B1 (OATP1B1), and Na
+/taurocholate co-transporting poly-
peptide (NTCP), using MPP
+, para-aminohippurate (PAH),
estrone-3-sulfate (ES), and taurocholic acid (TCA), respectively,
as the respective typical substrates. For the inhibition assay, the
uptake of each substrate in oocytes overexpressing the appropriate
Figure 1. Statistical analysis of urine metabolome of three different SLC22A2 genotypes. (A) Supervised multivariate analysis of urine
metabolite profiles among SLC22A2 genotypes. Partial least square analysis was performed with metabolomic profiles of urine samples. Component 1
indicates principal component 1 that can explain the most variation in dataset. Likewise, component 2 and component 3 indicate principal
component 2 and 3 respectively. Grey, green, and blue colors present the SLC22A2 reference, heterozygous, and homozygous genotype groups
respectively. (B) Multi-comparison analysis of uridine and tryptophan in urine from individuals with three SLC22A2 genotypes. Of the metabolites
showing significant differences among genotypes, uridine (left panel) and tryptophan (right panel) were the most significantly decreased in SLC22A2
808GT and 808TT, respectively. Data, assuming normal distributions, are displayed by box-whisker plots, giving the arithmetic mean for each category,
the standard error as a box, and whiskers for 1.96 times the category standard error to indicate the 95% confidence intervals. Bars sharing a symbol
are different at p,0.05 by Scheffe ´’s post-hoc test.
doi:10.1371/journal.pone.0036637.g001
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tryptophan at 0, 1.0, and 10.0 mM. Tryptophan significantly
inhibited MPP
+ uptake by OCT1, but it did not alter OAT1-
mediated PAH uptake (400 nM), OATP1B1-mediated ES uptake
(18.5 nM), or NTCP-mediated TCA uptake (1.5 mM) (Figure 6).
The significant inhibitory effect of tryptophan on OCT1-mediated
uptake of MPP
+ occurred in a concentration-dependent manner,
with 50% and 70% inhibition at 1 and 10 mM tryptophan,
respectively.
Tryptophan translocation rates were also measured using the
same transporters as those used in the inhibition assay. OCT1-
Figure 2. Visualization of the rCCA results of metabolites and pharmacokinetic parameters involved in metformin disposition. The
canonical structure correlations of 85 metabolites detected by GC-MS, and eight PK parameters with the first two canonical variates show a distinct
association between metabolites with PK parameters. The metabolites and PK parameters that presented higher than the threshold (canonical
correlation, .0.7) are colored in red and blue, respectively. The metabolites are tryptophan, citrulline, urea, free fatty acids (palmitate and stearate), 3-
hydroxy-3-methylglutaric acid, 3-hydroxypropionic acid, and conduritol-beta-epoxide. The PK parameters positively associated with the metabolite
cluster are Vd/F/kg, Clrenal,C l sec, and Cl/F/kg. Both AUClast and Cmax were located in the opposite direction from the cluster. HMG, 3-hydroxy-3-
methylglutaric acid; Trp, tryptophan; OHP, 3-hydroxypropionic acid; CBE, conduritol-beta-epoxide; Cmax, peak plasma concentration; AUClast, area
under the plasma concentration vs. time curve; Ke, elimination rate constant; Cl/F/kg, body weight-normalized clearance; Vd/F/kg, body weight-
normalized volume of distribution; Clrenal, renal clearance; Clcre, creatinine clearance; Clsec, secretion clearance.
doi:10.1371/journal.pone.0036637.g002
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0.85 fmol/min/oocyte (Figure S3).
4. Absolute quantification of tryptophan in urine
samples, by liquid chromatography-coupled tandem
mass spectrometry
Tryptophan levels in the urine samples of individuals carrying
different SLC22A2 genotypes were absolutely quantified by
selected reaction monitoring with liquid chromatography-coupled
tandem mass spectrometry (LC-MS/MS). As shown in Figure 7,
the absolute amounts of tryptophan in urine samples differed
significantly according to SLC22A2 genotype, with the highest
level measured in the reference group (57866968 mg), followed
in order by the 808GT (42876920 mg) and 808TT groups
(37186499 mg).
Discussion
The goal of the present study was to identify endogenous
substrates of the transporter OCT2 by 1) detecting metabolites
differentially present in urine samples collected from carriers of
three different SLC22A2 genotypes (reference group, heterozy-
gotes, and homozygotes); 2) determining linear associations
between the altered metabolites and metformin PK parameters;
and 3) evaluating the inhibitory potential and substrate specificity
of the identified metabolites in vitro.
Altered metabolite levels in urine samples may reflect
differential activity of transporters. To detect differentially
regulated metabolites among three SLC22A2 genotypes, we
applied non-targeted metabolite profiling in urine samples from
carriers of the reference SLC22A2 genotype and two variant
genotypes, 808GT and 808TT. Uridine and tryptophan were the
Figure 3. Network visualization of rCCA results. The network was constructed using a pairwise linkage score between metabolites and
metformin PK parameters. Red lines represent positive correlations (canonical correlation, .0.65), and the thickness is proportional to the level of
linearity. Nodes for metabolites and PK parameters are squares (blue) and circles (purple), respectively, and the size of node indicates the level of
connectivity. Blue dot lines were additionally linked in order to present negative association which is below the threshold. Trp, tryptophan; Rib,
ribose; Glc, glucose; Tau, taurine; HMG, 3-hydroxy-3-methylglutaric acid; G3G, glycerol-3-galactoside; Anhydroinositol, 1,2-anhydro-myo-inositol;
deoxyerythritol, 2-deoxyerythritol; OHP, 3-hydroxypropionic acid; psiUridine, pseudo-uridine.
doi:10.1371/journal.pone.0036637.g003
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808GT and 808TT variants, compared with the levels in the
reference group. Tryptophan showed a gradual decrease accord-
ing to the order of genetic variation (reference group.808GT
heterozygotes.808TT homozygotes), suggesting a gene-dose
effect on OCT2 transporter activity, which may be specific for
tryptophan.
The disposition of metformin has been reported to be affected
by SLC22A2 genotype, leading us to hypothesize that metabolites
closely correlated with metformin PK parameters may be
endogenous substrates of OCT2. Linear associations between
Figure 4. Comparison of the inhibition of OCT2-mediated MPP
+ uptake by the metabolites at multiple concentration ranges. (A)
Inhibitory effect of TEA (0.1–1000 mM), glycine (1–100 mM), taurine (1–100 mM), L-tryptophan (0.01–10 mM), and uridine (1–100 mM) on OCT2-
mediated MPP
+ uptake. (B) Concentration-dependent inhibitory effect of L-tryptophan (0.01–10 mM) on the uptake of 18.5 nM [
3H]MPP
+ in oocytes
expressing OCT2. (C) Concentration-dependent inhibitory effect of uridine (1–100 mM) on the uptake of 18.5 nM [
3H]MPP
+ in oocytes expressing
OCT2. IC50 was calculated by non-linear regression analysis using an inhibitory effect Emax model: v=Emax2Emax6C/(IC50+C). Data represent means 6
standard error (SE) of eight independent experiments.
doi:10.1371/journal.pone.0036637.g004
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determined by CCA, which allows for quantifying the level of
coordination between two different parametric readouts. Among
the group of metabolites found to be closely associated with four
metformin PK parameters (Clrenal,C l sec, Cl/F/kg, and Vd/F/kg;
canonical correlation, .0.70), tryptophan showed the greatest
linear relatedness to all four, especially to Vd/F/kg (canonical
correlation, 0.804). Tryptophan also demonstrated a moderate
negative correlation with AUClast. The strong correlations
between the tryptophan level and metformin PK parameters
indicated that it may be a potential substrate of OCT2.
Prior to in vitro function study, which is the comparably slow and
laborious stage, we validated the significance of the findings by
comparing the result with other type of data normalization,
creatinine-level. Recent publications report the limited application
of creatinine level-normalization due to the significant variability
of the levels depending on age, gender, and time point [20–22].
However, we selected the method since it has been a common
method along with urine-volume normalization [23,24], and also
different statistics can provide more reliable data interpretation
[25]. In general, we reproduced the compatible pattern to the
urine volume-normalized result such as compatibility of normal-
ization factor and variable distribution (Text S1). At the same
time, we observed the dissimilarity between datasets differentially
normalized such as the detailed list of significantly altered
compounds, and also the superiority of reproducibility in
biological replicate in the urine volume-normalized data set (Text
S1). Nonetheless, we selected tryptophan for following in vitro
function study based on its greatest alteration with gene-dose effect
(in urine normalization) and the strongest linkage to the PK
parameters (in both normalization). Uridine and taurine were also
considered since they showed consistent result in univariate
analysis (the greatest significance) and rCCA in which moderate
levels were found in the association with the PK parameters. Note
that the consistency of rCCA outcome implies a great advantage of
the multivariate statistics (rCCA) over univariate statistics that
could bias result interpretation driven by data normalization types.
We further narrowed down the candidates based on prior
knowledge and simultaneous consideration of two statistical
criteria (significant alteration and strong association with the PK
parameters of metformin). For example, we did not consider
xanthine and xanthosine because they both indicated very poor
association with the PK parameters. Citrulline was not included
for the function study since it has been reported as the substrate for
organic anion transporter 1 (OAT1) [26]. Instead, glycine was
further assessed as a representative negative control as it only
presented the significant alteration but weak correlation with the
PK parameters so that we can evaluate the benefit of additional
statistics, regularized-canonical correlation analysis (rCCA).
Accordingly, in the evaluation of their ability to inhibit MPP+
uptake by OCT2, tryptophan showed the greatest inhibition, with
an IC50 of 6.11 mM while merely moderate inhibitory effect was
detected in uridine with a much higher IC50 (51.5 mM) and no
effect in taurine and glycine. This in vitro function result
circuitously evidenced the suitability of data analysis preferentially
used in our study (urine volume-wise normalization), and the
powerful benefit of rCCA statistics which can precisely predict the
potential candidate of a transporter by characterizing linkage of
metabolites and the pharmacokinetic parameters associated with
metformin disposition. The following tryptophan uptake experi-
ments in oocytes overexpressing the OCT2 reference and
808G.T variant confirmatively revealed significantly lower
uptake and a significantly slower translocation rate with the
variant protein than with the reference protein.
In subsequent inhibition assay to verify the specificity of
tryptophan for OCT2, tryptophan inhibited OCT1-mediated
uptake of MPP
+, but not the transport function of OAT1,
OAT1B1, or NTCP. In tryptophan uptake experiments, OCT1
facilitated the translocation of tryptophan, whereas OAT1,
OAT1B1, and NTCP did not. OCT1 and OCT2 share about
70% sequence similarity and have a similar broad range of
substrates [10,27–29], which may include tryptophan. However,
OCT1 and OCT2 can be distinguished based on differential
affinities for selected substrates and different tissue distributions
[10,30,31]. OCT1 is expressed primarily in the sinusoidal
membrane of hepatocytes, while OCT2 is expressed mainly in
the basolateral membrane of kidney proximal tubules. Thus,
OCT1 and OCT2 are thought to play critical roles in the biliary
and renal excretion of organic cationic substances in the liver and
kidney, respectively [32]. In the present study, tryptophan was
a stronger inhibiter of OCT2 transport activity than OCT1
transport activity, and OCT2-mediated tryptophan uptake was
greater than that mediated by OCT1. Together, the data suggest
that compared with OCT1, OCT2 has higher binding affinity and
transport activity for tryptophan.
Finally, the absolute quantification of tryptophan by LC-MS/
MS showed the highest tryptophan levels in urine samples from
SLC22A2 reference carriers, followed by 808GT heterozygotes and
then 808TT homozygotes.
Collectively, the findings in the present study indicate that
variations of the SLC22A2 genotype may modulate the uptake of
tryptophan. The decreased transport function associated with the
SLC22A2 variants results in decreased renal clearance of
tryptophan, leading to decreased renal concentrations of trypto-
phan, as previously observed for metformin. Additionally, in vitro
functional studies of the inhibition potential and uptake rate of
tryptophan strongly suggest that it is a specific endogenous
substrate of OCT2 and consequently a potential biomarker of
genotype-dependent OCT2 transport activity. Furthermore, the
present study demonstrates that non-targeted metabolite profiling
can serve as a robust pre-screening tool for potential transporter
substrates, thus reducing the time and effort required for in vitro
and in vivo functional studies.
Figure 5. Differential tryptophan uptake rate in oocytes
overexpressing the OCT2 reference and 808G.T variant.
Uptake of (A) 100 nM [
3H]tryptophan or (B) 18.5 nM [
3H]MPP
+ by
oocytes overexpressing the OCT2 reference or 808G.T variant.
Defolliculated oocytes were injected with 50 ng of capped cRNA and
incubated for 2 days. Uptake was measured for 30 min. Data represent
means 6 SE of eight independent experiments. * P,0.05, compared
with OCT2 reference using Student’s t-test.
doi:10.1371/journal.pone.0036637.g005
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1. Chemicals
[5-
3H]L-Tryptophan (61 mCi/mmol), N-[methyl-
3H]-4-phenyl-
pyridinium acetate (MPP
+, 81 Ci/mmol), [
3H]para-aminohippu-
rate (PAH, 4.6 Ci/mmol), [
3H]estrone-3-sulfate (ES, 57 Ci/
mmol), and [
3H]taurocholate (TCA, 1.7 Ci/mmol) were pur-
chased from Perkin Elmer Life Science (Boston, MA). Unlabeled
tryptophan, L-tryptophan-d5, MPP
+, PAH, ES, and TCA were
purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO).
Fatty acid methyl esters (retention time index markers: C8, C9,
C10, C12, C14, C16, C18, C20, C22, C24, C26, C28, and C30)
and 98% pure methoxyamine hydrochloride (CAS No. 593-56-6)
were from Sigma-Aldrich. N-Methyl-N-trimethylsilyl-trifluoraceta-
mide (MSFTA) with 1% trimethylchlorosilan (TMCS) was
obtained from Pierce (Rockford, IL). High-performance liquid
chromatography-grade acetonitrile and water were purchased
from JT Baker (Phillipsburg, NJ). All other chemicals and solvents
were of the highest analytical grade available.
2. GC-time of flight (TOF) MS analysis for metabolites
Urine samples for metabolomic analysis were obtained from our
previous study, which was performed to elucidate the influence of
genetic variants of SLC22A2 on the disposition of metformin [17].
The study protocol was approved by the Institutional Review
Board of Inje University Busan Paik Hospital, Busan, Korea. All
the subjects provided written informed consent before participat-
ing in the study. The genotypes of the subjects were SLC22A2
reference (n=9), 808GT heterozygous (n=6), and 808TT
homozygous (n=6). Urine samples were collected for 12 h and
stored at 280uC prior to extraction. The endogenous primary
metabolites in urine were profiled by GC-TOF as previously
described, with some modifications [33]. Briefly, urine aliquots
(15 mL) were extracted using 1 mL of acetonitrile:isopropanol:-
water (3:3:2; v/v/v) at 220uC, and centrifuged. The supernatants
were collected, and the solvent was evaporated to complete
dryness. A clean-up step with 500 mL of acetonitrile/water (1:1; v/
v) was applied to remove membrane lipids and triglycerides, and
the sample was dried again. A mixture of internal retention index
(RI) markers was prepared using fatty acid methyl esters of C8,
Figure 6. Inhibitory effect of tryptophan on transporter uptake. Inhibitory effect of 1 or 10 mM tryptophan on (A) OCT1-mediated MPP
+
uptake (18.5 nM), (B) OAT1-mediated PAH uptake (400 nM), (C) OATP1B1-mediated ES uptake (18.5 nM), and NTCP-mediated TCA uptake (1.5 mM).
Mock: Water-injected oocyte. Control: Oocytes expressing OCT1, OAT1, OATP1B1, or NTCP without tryptophan. Trp: Tryptophan. Data represent
means 6 SE of eight independent experiments. * P,0.05, compared with water-injected oocytes using Student’s t-test.
doi:10.1371/journal.pone.0036637.g006
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C30 linear chain lengths dissolved in chloroform at a concentration
of 0.8 mg/ml (C8–C16) or 0.4 mg/mL (C18–C30). A total of
1 mL of RI mixture was added to the dried extracts. Next, 10 mL
of a solution of 40 mg/mL of 98% pure methoxyamine
hydrochloride in pyridine (silylation grade; Pierce) were added
and shaken at 30uC for 90 min, to protect aldehyde and ketone
groups. Then, 90 mL of MSTFA with 1% TMCS were added and
shaken at 37uC for 30 min, for trimethylsilylation of acidic
protons. A Gerstel automatic liner exchange system with
a multipurpose sample MPS2 dual rail was used to inject 0.5 mL
of the sample into a Gerstel CIS cold injection system (Gerstel,
Muehlheim, Germany). The injector was operated in the splitless
mode, opening the split vent after 25 s and then ramping up to
250uC. Analytes were separated using an Agilent 6890 gas
chromatograph (Santa Clara, CA) equipped with a 30-m long,
0.25-mm i.d. Rtx5Sil-MS column (0.25 mm of 5% diphenyl film
and an additional 10-m integrated guard column; Restek,
Bellefonte, PA). Mass spectrometry was performed using a Leco
Pegasus IV TOF mass spectrometer (St. Joseph, MI) with a transfer
line temperature of 280uC, electron ionization at 270 eV, and an
ion source temperature of 250uC. Mass spectra were acquired
from m/z 85 to 500 at 17 spectra s
21 and 1850 V detector voltage.
The files were preprocessed directly after data acquisition and
stored as ChromaTOF-specific *.peg files, generic *.txt result files,
or generic ANDI MS *.cdf files. The files were processed using the
metabolomics BinBase database [34]. All database entries in
BinBase were matched against the Fiehn mass spectra library of
,1,200 authentic metabolite spectra, using the retention index
and mass spectrum information, or the NIST05 commercial
library. Identified metabolites were reported when present in at
least 80% of the samples per study design group (as defined in the
SetupX database) [35].
3. Statistical data analysis
Statistical analyses were performed on all continuous variables,
which were normalized by excreted urine volume collected for
12 hr, using Statistica software v. 8.0 (StatSoft, Tulsa, OK). In
addition data set was normalized with creatinine level and tested
for statistical validation of the result. Univariate statistics for
multiple study design classes were performed using Student’s t-test
breakdown and one-way ANOVA, and Scheffe ´’s multi-compar-
ison analysis. Data are displayed as box-whisker plots, giving the
arithmetic mean for each category with the standard error as a box
and whiskers for 1.96 times the category standard error.
Multivariate statistics were performed by unsupervised principal
component analysis (PCA) and supervised partial least square
(PLS) statistics, which require information regarding the assigned
study classes. As classical canonical correlation analysis (CCA)
cannot be simultaneously performed with large data sets due to
numerical limitations (e.g., the numbers of samples and variables),
a regularized version of CCA, which is available in the CCA
package [36] for the statistical software R, was used. CCA seeks to
recognize correlations between two different sources of data sets.
Given a set of metabolites and a set of PK parameters of
metformin, the primary aim of CCA is to identify two linear
combinations, one for the set of metabolites and one for the set of
PK parameters that are maximally co-varianced. For visualization,
two-dimensional scatter plots (canonical loadings plots) were used
for the PK parameters and metabolites. The axes present the
canonical variates that can be determined by scree plots. Here, the
data were normalized using the values mean-centered and divided
by the standard deviation of each variable. As both PK parameters
and metabolites are assumed to be of unit variance, their
projections on the plane are located within a circle of radius 1
and centered at the origin. Variables with a strong relation are
projected in the same direction from the origin, such that the
greater the distance from the origin, the stronger is the relation. A
second circle with radius of 0.5 is shown to indicate weaker
associations of metabolites and PK parameters. For detailed
information on the linearity of each variable set (metabolite-PK
parameter), a network was generated using pairwise correlation
between metabolites and PK parameters [37]. Edges indicate
linear associations with cutoff .0.65, and nodes with a circle or
square represent metabolites or PK parameters, respectively.
4. Assay of tryptophan concentrations using liquid
chromatography-tandem mass spectrometry
Tryptophan concentrations in urine samples were quantified
using liquid chromatography-tandem mass spectrometry (LC-MS/
MS; API 3000; Applied Biosystems, Foster City, CA). Briefly,
aliquots of urine samples (40 mL) were extracted by addition of
120 ml of ice-cold methanol containing 1,000 ng/mL tryptophan-
d5 as an internal standard and 0.13 N HCl. After centrifugation
(14,000 rpm for 10 min at 4uC), aliquots (2 mL) of the supernatant
were analyzed by LC-MS/MS. The analytes were separated on
a reversed-phase column (Atlantis dC18, 2.1 mm i.d.6150 mm, 3-
mm particle size; Waters, Milford, MA) with an isocratic mobile
phase consisting of acetonitrile and water (30:70, v/v) containing
0.1% formic acid. The mobile phase was eluted at 0.2 ml/min,
using an Agilent 1100 series pump (Agilent, Wilmington, DE). The
turbo ion spray interface was operated in the positive ion mode at
5500 V and 400uC. Operating conditions were optimized by flow
injection of a mixture of all analytes and were determined as
follows: nebulizing gas flow, 40 psi; curtain gas flow, 10 psi; and
collision energy, 20 eV. Quadruples Q1 and Q3 were set on unit
resolution. Quantitation was performed by selected reaction
monitoring of the protonated precursor ion and the related
product ion for tryptophan, using the internal standard method.
The mass transitions used for tryptophan and tryptophan-d5 were
m/z 205R188 and 210R192, respectively. The analytical data
Figure 7. Absolute levels of tryptophan in urine samples.
Tryptophan levels were measured from SLC22A2 reference (n=9), 808GT
(n=6), and 808TT (n=6) carriers using selected reaction monitoring
with liquid chromatography-coupled tandem mass spectrometry. The
boundary of the box closest to zero indicates the 25
th percentile, a line
within the box marks the median, and the boundary of the box farthest
from zero indicates the 75
th percentile.
doi:10.1371/journal.pone.0036637.g007
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curves in urine provided a reliable response from 100 to
200,000 ng/mL. Inter-assay precision values for tryptophan
analysis in urine samples were less than 15.0%.
5. Uptake of tryptophan and MPP
+ in oocytes expressing
OCT2 reference and variant
The synthesis of cRNA and uptake experiments were performed
as described previously [27]. Briefly, capped cRNAs were
synthesized in vitro using T7 RNA polymerase with linear plasmid
DNA containing the reference and variants of OCT2 (pcDNA3.1-
SLC22A2-reference and 2808G.T). Defolliculated oocytes were
injected with 50 ng of the capped cRNA and incubated at 18uCi n
Barth’s solution (88 mM NaCl, 1 mM KCl, 0.33 mM Ca(NO3)2,
0.4 mM CaCl2, 0.8 mM MgSO2, 2.4 mM NaHCO3,1 0 m M
HEPES, pH 7.4) containing 50 mg/mL gentamicin and 2.5 mM
pyruvate. After incubation for 2 days, uptake experiments were
performed at room temperature in ND96 solution (96 mM NaCl,
2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES,
pH 7.4) containing [
3H]tryptophan (100 nM) or [
3H]MPP
+
(18.5 nM). After washing five times, the oocytes were solubilized
with 10% SDS, and the radioactivity in the oocytes was analyzed.
The uptake of tryptophan and MPP
+ mediated by the OCT2
reference and variant was calculated by subtracting the uptake rate
of water-injected oocytes from that of OCT2-expressing oocytes.
Inhibition of the uptake of 18.5 nM [
3H]MPP
+ by various
concentrations of TEA (0.01–1 mM), glycine (1–100 mM), taurine
(1–100 mM), and tryptophan (0.01–10 mM) was measured in
oocytes expressing OCT2. The affinity of tryptophan for OCT2
was assessed by measuring the concentration of tryptophan that
inhibited uptake of MPP
+ by 50% (IC50 value). The inhibitory
effect of tryptophan on the transport activities of OCT1, OAT1,
OATP1B1, and NTCP was determined by measuring the OCT1-
mediated MPP
+ uptake (18.5 nM), OAT1-mediated PAH uptake
(400 nM), OATP1B1-mediated ES uptake (18.5 nM), and NTCP-
mediated TCA uptake (1.5 mM) in the presence of tryptophan (1
and 10 mM). OCT1, OAT1, OATP1B1, and NTCP were
expressed in oocytes as described previously, using linearized
plasmids pcDNA3.1-OCT1, -OAT1, -OATP1B1, and -NTCP as
templates.
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